

## Discovery Report

Patent: EVE-PAT-2026-001 | Organiq Sweden AB

## 1 - DISCOVERY

QUERY	TYPE 2 auto-scan: Similarity bridge: ceritinib entrectinib via FLT3, NTRK1, RET +7 more
COMPOUND	CERITINIB
DISCOVERY SCORE	27.000
ENGINE	DISCOVERY_v1.2
CORPUS VERSION	v20260506-01
GENERATED	2026-05-14T03:00:00.933Z

## 2 - EVIDENCE

TARGETS	FLT3, NTRK1, RET, JAK2, NTRK2, IGF1R, INSR, ROS1, ALK, JAK3
PATHWAYS	—
EVIDENCE SCORE	0.00
STUDIES	0

## X-VAULT EVIDENCE SEAL

SYSTEM	BiohacksAI   XVAULT_v1
DISCOVERY ID	disc_T2_ceritinib_entrectinib_1879f052
EVENT HASH	75430b0913ad4ec6...aff42732
CHAIN HASH	ad1188a1d7de58e2...07eb3d65
PREV HASH	643ee45033927e1e...25264c4f
CORPUS VERSION	v20260506-01
CORPUS ROOT	6178ce3d1b9ff52e...d1c9a225
VAULT INDEX	2997
SEALED AT (UTC)	2026-05-14T03:00:00.960Z

## - VERIFICATION

This document is cryptographically sealed by the BiohacksAI X-Vault Evidence Engine. The discovery payload hash and corpus Merkle root can be independently verified.

Verify at: [eveverified.com/verify](https://eveverified.com/verify)

Verification fingerprint: 75430b0913ad4ec6...aff42732

